TENX Canaccord initiated coverage of Tenax Therapeutics with a Buy rating and $35 price target. Tenax is a clinical-stage biopharma developi
TENX Canaccord initiated coverage of Tenax Therapeutics with a Buy rating and $35 price target. Tenax is a clinical-stage biopharma developing TNX-103 for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction, a large underserved market with no currently approved therapi